Statistics show that in the past ten years, with the rapid development of my country's economy and the continuous improvement of people's living standards, coupled with the intensification of the aging population, people's demand for medical care has continued to grow, prompting the rapid development of the domestic pharmaceutical market.

  In 2014, the scale of China's pharmaceutical market exceeded 1.1 trillion yuan, and in 2019 it has reached about 1.64 trillion yuan. It is predicted that China's pharmaceutical market will continue to maintain a growth rate comparable to that of previous years, and reach about 2.13 trillion yuan in 2023. my country's pharmaceutical industry has made remarkable progress in the past ten years, and is in a stage of rapid growth, with a broad market space in the future.

  China's pharmaceutical market has now grown into the world's second largest pharmaceutical market after the United States. According to the chart produced by China Galaxy Securities Research Institute, the main income of my country's pharmaceutical manufacturing industry continues to grow rapidly. Although the growth rate has gradually slowed down in recent years, the Still much higher than the growth rate of GDP in the same period.

  Although China's medical demand is growing rapidly, there is still a lot of room for improvement in the ratio of China's medical expenditure to GDP. According to statistics from the World Bank, China's medical expenditure accounted for 4.98% of GDP in 2016, far below the world average of 10.02%. In the United States and Japan, which are developed countries, the ratio of medical expenditure to GDP is 17.07% and 10.93% respectively.

  With the growth of China's economy, the improvement of residents' income, the enhancement of medical awareness, and the intensification of population aging, the proportion of China's medical expenditure in GDP will gradually increase.

  The aging population will become an important driving force to promote the growth of demand in China's pharmaceutical market

  At present, the middle-income group with a population of 400 million in China is expected to become the main force to promote the sustained and stable growth of my country's pharmaceutical market in the next 20 years as they grow older. Since the founding of New China, there have been three waves of baby boomers: the first wave 1950-1958; the second wave 1962-1973; the third wave 1986-1990.

  Relying on the demographic dividend brought about by these three waves of baby boomers, China’s economy has made great achievements since the reform and opening up, becoming the world’s second largest economy. The continuous development over the past few decades has made outstanding contributions.

  Now that the time has entered 2021, the first wave of baby boomers has retired, and the second wave of baby boomers has gradually begun to enter the year of destiny. For this group of people, the greatest need at present is to improve the quality of life and not suffer from illness.

  According to the data from the National Bureau of Statistics, as of the end of 2019, my country had about 254 million people over the age of 60, ranking first in the world, accounting for 18.1% of the total population, and this number will continue to grow rapidly in the future. According to the "Green Paper on Population and Labor: Report on China's Population and Labor Issues No.

  From 2010 to 2040, the elderly population will increase by a total of 224 million people, with an average annual net increase of 7.46 million, and the aging level will reach 23.84% in 2040. This part of the large-scale and fast-growing elderly population has accumulated a certain amount of wealth during the process of China's reform and opening up in the past few decades. They are willing and able to enjoy high-quality medical services, so personal medical services The increase in demand will become an inevitable trend.

  It can be seen that the future market development space of China's medical industry is huge and the continuous cycle is long. With the world's largest and still growing elderly population, the proportion of my country's medical and health expenditures in GDP will continue to increase, and the market size of the medical industry will also expand simultaneously.

  In the context of the three waves of baby boomers entering the aging stage, the medical industry is expected to usher in a golden period of development for at least 20 years.

  The new crown epidemic has prompted a substantial increase in my country's exports of new crown pneumonia prevention and control drugs and epidemic prevention materials

  Due to the remarkable effect of traditional Chinese medicine in this anti-epidemic action, the revival of my country's traditional Chinese medicine industry has been accelerated. As a treasure of our country's traditional culture, traditional Chinese medicine has had a wide range of participation, a deep participation, and a high degree of attention in the treatment of new coronary pneumonia, which is unprecedented since the founding of the People's Republic of China.

  Because traditional Chinese medicine has shown good effects in preventing mild and ordinary patients from developing into severe and critical patients, as well as in the treatment of severe and critical patients, especially in reducing high fever, promoting exudate absorption, and increasing carbonation levels. , the effect of reducing pulmonary fibrosis is more significant.

  As a result, TCM diagnosis and treatment and TCM are being accepted by the international community. According to reports, since the outbreak of the epidemic, countries such as South Korea, Japan, and Italy hoped that China would share experience in the use of traditional Chinese medicine and requested assistance in the use of traditional Chinese medicine; the media in Hungary, India, Singapore, Malaysia and other countries praised the remarkable curative effect of traditional Chinese medicine in the epidemic Plus.

  The data shows that my country's export volume of Chinese herbal medicines has achieved a relatively large increase during the epidemic. From January to July 2020, my country's total export of medical and health care products was US$50.08 billion, a year-on-year increase of 17.5%.

Since the second quarter of 2020, the spread of the overseas epidemic has led to a rapid increase in the international demand for my country's pharmaceutical products, especially the rapid growth of drugs related to the prevention and treatment of pneumonia and epidemic prevention materials.

  The epidemic has made people realize that medical services are just needed, prompting all people to pay more attention to their own health.

  Affected by the epidemic, people are currently paying more attention to their own health. Before the outbreak of the epidemic, many people were deeply affected by material needs in their lives. They pursued too much material enjoyment in life, and most of them ignored their own health problems. The sudden arrival of the new crown epidemic made many people wake up suddenly.

  The wealth and other material enjoyments they pursue are not worth mentioning in front of health. In a critical moment that concerns people's lives, having money may not necessarily save lives. Therefore, the epidemic has made each of us start thinking about health issues. It also made most people realize the importance of health.

  China is the largest pharmaceutical market in the world, but currently the research and development and consumption of innovative drugs in the global biomedical field are mainly in the United States. In the future, as my country's innovative drugs are more included in commercial insurance, the Chinese pharmaceutical market will have huge room for development. In addition, the huge clinical market is also the biggest advantage for China's future batch of biomedical frontiers to compete in the world.

  With the advancement of mobile communication technology, the demand for Internet medical services has surged, and online medical platforms have ushered in opportunities for development. Due to the impact of the epidemic, Internet online medical care may usher in a round of growth opportunities.

  The growth of pharmaceutical companies needs to invest a lot of money and time. At present, compared with the global developed countries and the leading pharmaceutical companies in the United States, the investment of Chinese pharmaceutical companies in research and development is far from enough. China's pharmaceutical market has broad prospects for development.

  Enterprises with investment value in the future must have core R&D capabilities, be full of innovative spirit, and dare to invest a lot of money in R&D.